Particle Sciences adds sterile powder filling and capsule filling capabilities
Powder fills from 50 mg to 75 g, with an accuracy of up to +/- 1% of fill volume, are now possible, including those for highly potent compounds.
The Lubrizol Corporation’s LifeSciences business has added cGMP sterile powder filling and capsule filling at their Particle Sciences facility.
“In response to client needs, we are expanding our cGMP powder handling capabilities. There has been an uptick in our partners’ need for sterile powder filling, both in vials and proprietary devices. To meet this need, we have acquired and qualified the necessary equipment. Powder fills from 50 mg to 75 g, with an accuracy of up to +/- 1% of fill volume, are possible, including those for highly potent compounds,” explains Robert W. Lee, vice president of pharmaceutical development services.
As the leading developer of particulates, utilizing both standard and proprietary approaches, the Particle Sciences’ facility is supported by full development and analytic services. Commercial production at that location will come online in 2017.
“Also included in this latest capability expansion is capsule filling. With a clinical supply capability of 3,000 capsules (sizes 0–4) per hour, we are positioned to assist our clients in utilizing our bioavailability-enhancing platforms in oral dosage forms,” Lee adds.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.